GSK to Acquire Nuvalent for $10.6B
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- GSK announced it will acquire cancer‑focused biotech Nuvalent for $10.6 billion, expanding its oncology pipeline.
- GSK is paying $124 per share, a 26 % premium to Nuvalent’s average price over the past 30 days.
- GSK will fund the deal with about $9.4 billion in cash.
- GSK’s purchase is among the largest recent biopharma acquisitions and its biggest deal in years.
- Nuvalent is a Cambridge, Massachusetts‑based biotech focused on targeted cancer therapies.
Why it matters: GSK secures Nuvalent’s targeted cancer portfolio, paying $124 per share—a 26 % premium—and $9.4 billion in cash, giving the firm a new pipeline to offset generic pressure while delivering a premium payout to Nuvalent shareholders. The acquisition also underscores the broader industry trend of large firms buying midsize biotechs to replenish pipelines as blockbusters near expiry.
Ask SkimNews
